drugset

Drugs / Vemircopan

Follow last change Dec 2024 re-read 9 days ago

Vemircopan

also known as ALXN2050 · ACH-0145228 · ACH-5228

Developed for: generalized myasthenia gravis · IgA glomerulonephritis · lupus nephritis · paroxysmal nocturnal hemoglobinuria
Investigated by: Alexion Pharmaceuticals, Inc. · Achillion, a wholly owned subsidiary of Alexion · Celerion

Trials 16

today NCT06071442 · Ph 1 NCT05780645 · Ph 1 NCT05218096 · Ph 2 NCT05259085 · Ph 1 NCT05097989 · Ph 2 NCT05202145 · Ph 1 NCT04952545 · Ph 1 NCT04623710 · Ph 1 NCT04933682 · Ph 1 NCT04609670 · Ph 1 NCT04660890 · Ph 1 NCT04551586 · Ph 1 NCT04709081 · Ph 1 NCT04170023 · Ph 2 NCT05047484 · Ph 1 NCT05047458 · Ph 1

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 113 trials
Phase 1	NCT06071442	Jan → Apr 2024	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT05780645	Mar 2023 → Feb 2024	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT05259085	Apr 2022 → Aug 2024	—	Alexion Pharmaceuticals, Inc.	Terminated	No outcome recorded Stop: Business
Phase 1	NCT05202145	Jan → Mar 2022	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04952545	Jul → Sep 2021	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04623710	Jul 2021 → Feb 2022	impaired renal function disease	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04933682	Jun → Aug 2021	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04609670	Apr → Aug 2021	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04660890	Dec 2020 → Mar 2021	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04551586	Jun → Oct 2020	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04709081	Dec 2019 → Apr 2020	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT05047484	Jan → Jul 2019	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT05047458	Nov 2017 → Apr 2018	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded

Phase 23 trials · 1 met primary · 2 missed
Phase 2	NCT05218096	Apr 2022 → Nov 2023	generalized myasthenia gravis	Alexion Pharmaceuticals, Inc.	Terminated	Missed primary Stop: Business
Phase 2	NCT05097989	Jan 2022 → Dec 2024	IgA glomerulonephritis, lupus nephritis	Alexion Pharmaceuticals, Inc.	Terminated	Missed primary Stop: Business
Phase 2	NCT04170023	Dec 2019 → Apr 2023	paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.	Terminated	Met primary

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2022-11-30	AstraZeneca	Results AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 astrazeneca.com ↗ An oral presentation detailing interim results from a Phase II open-label trial of vemircopan (ALXN2050) will highlight efficacy and safety data from the treatment-naïve patient group, establishing proof-of-concept as a monotherapy for PNH.

All press releases naming this drug 1 release

Date	Issuer	Release
2022-11-30	AstraZeneca	AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 astrazeneca.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	Vemircopan	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06071442 ↗
Known as	ACH-0145228	“A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal...” NCT04170023 ↗ 2 NCT04709081 ↗ NCT04551586 ↗
Known as	ACH-5228	ChEMBL registry synonym — accepted as the source's own label CHEMBL4650325 ↗
Known as	ALXN2050	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05259085 ↗ 12 NCT04609670 ↗ NCT04933682 ↗ NCT05218096 ↗ NCT04660890 ↗ NCT05780645 ↗ NCT05097989 ↗ NCT05047484 ↗ NCT04623710 ↗ NCT04170023 ↗ NCT05202145 ↗ Show 2 more sources
Action	Inhibit	“Oral FD inhibitor” NCT04170023 ↗
Modality	Small molecule	— CHEMBL4650325 ↗
Route	Oral	“ALXN2050 orally administered” NCT04170023 ↗